Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma

被引：0
|
作者：
Le Ngoc Ha
Amir Iravani
Nguyen Thi Nhung
Ngo Thi Minh Hanh
Febby Hutomo
Mai Hong Son
机构：
[1] 108 Central Military Hospital,Department of Nuclear Medicine
[2] Washington University School of Medicine,Department of Pathology
[3] Mallinckrodt Institute of Radiology,Nuclear Medicine Department
[4] 108 Central Military Hospital,undefined
[5] MRCCC Siloam Hospital,undefined
来源：
Cancer Imaging | / 21卷
关键词：
F-fluorodeoxyglucose; BRAF ; mutation; Histopathologic type; Radioiodine-refractory; Differentiated thyroid carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Fluorine-18 FDG-PET for the detection of recurrent and/or metastatic 131-iodine negative thyroid carcinoma
    Flores, JA
    Becherer, A
    Kaserer, K
    Cerny, C
    Nowotny, C
    Pötzi, C
    Niederle, B
    Dudczak, R
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1093 - 1093
  • [42] Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
    Wang, Congcong
    Zhang, Ruiguo
    Wang, Renfei
    Meng, Zhaowei
    Zhang, Guizhi
    Dong, Feng
    He, Yajing
    Tan, Jian
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [43] The Relationship Between TSH Level and Stage of Differentiated Thyroid Carcinoma
    Tuncez, Esra
    Kulaksizoglu, Mustafa
    Tuncez, Ismail Hakki
    [J]. TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 24 (03) : 230 - 236
  • [44] Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
    Manohar, Poorni M.
    Beesley, Lauren J.
    Bellile, Emily L.
    Worden, Francis P.
    Avram, Anca M.
    [J]. CLINICAL NUCLEAR MEDICINE, 2018, 43 (09) : 641 - 647
  • [45] The role of FDG PET/CT in the management of metastatic/recurrent differentiated thyroid carcinoma patients, comparison with serum Thyroglobulin levels and histopathological characteristics
    Vural, G. Ucmak
    Akkas, B. E.
    Ercakmak, N.
    Aslan, S.
    Sasani, C.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S273 - S273
  • [46] 90Y-DOTATOC therapy in patients with metastatic radioiodine negative differentiated thyroid cancer: Preliminary results
    Versari, Annibale
    Filice, Angelina
    Frasoldati, Andrea
    Cremonini, Nadia
    Asti, Mattia
    Fioroni, Federica
    Fraternali, Alessandro
    Casali, Massimiliano
    Salvo, Diana
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [47] Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma
    Lee S.H.
    Han S.
    Lee H.S.
    Chae S.Y.
    Lee J.J.
    Song D.E.
    Ryu J.-S.
    [J]. Nuclear Medicine and Molecular Imaging, 2016, 50 (1) : 38 - 45
  • [48] Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma
    Pomerri, Fabio
    Cervino, Anna Rita
    Al Bunni, Faise
    Evangelista, Laura
    Muzzio, Pier Carlo
    [J]. RADIOLOGIA MEDICA, 2014, 119 (02): : 97 - 102
  • [49] Impact of FDG-PET Computed Tomography for Surgery of Recurrent or Persistent Differentiated Thyroid Carcinoma
    Weber, T.
    Ohlhauser, D.
    Hillenbrand, A.
    Henne-Bruns, D.
    Reske, S. N.
    Luster, M.
    [J]. HORMONE AND METABOLIC RESEARCH, 2012, 44 (12) : 904 - 908
  • [50] Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma
    Fabio Pomerri
    Anna Rita Cervino
    Faise Al Bunni
    Laura Evangelista
    Pier Carlo Muzzio
    [J]. La radiologia medica, 2014, 119 : 97 - 102
12345